Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Friday, LumiraDx Limited (NASDAQ:LMDX) appointed joint administrators for two subsidiaries. The administrators signed a definitive agreement to sell certain companies of LumiraDx related to LumiraDx's point-of-care technology to Roche Holdings AG (OTC: RHHBY).
週五，LumiraDX Limited（納斯達克股票代碼：LMDX）任命了兩家子公司的聯合管理人。管理人員簽署了一項最終協議，將某些與LumiraDX的即時醫療技術相關的LumiraDX公司出售給羅氏控股股份公司（場外交易代碼：RHHBY）。
Separately, LumiraDx appointed Andrew Johnson, Lisa Rickelton, and Lindsay Hallam of FTI Consulting as joint administrators of two subsidiaries, LumiraDx Group Limited and LumiraDx International Limited, which together hold substantially all of the assets of the LumiraDx group.
另外，LumiraDX任命FTI Consulting的安德魯·約翰遜、麗莎·裏克爾頓和林賽·哈勒姆爲兩家子公司LumiradX集團有限公司和LumiradX國際有限公司的聯合管理人，這兩家子公司共持有LumiradX集團的幾乎所有資產。
Roche will pay $295 million and an additional payment of up to $55 million for the reimbursement of amounts to fund the point-of-care diagnostics platform business until the closing of the acquisition.
在收購完成之前，羅氏將支付2.95億美元，並額外支付高達5500萬美元的款項，用於報銷爲即時診斷平台業務提供資金的款項。
The completion of the transaction is subject to certain conditions, including antitrust and regulatory approvals, and is currently expected to close by mid-2024.
該交易的完成取決於某些條件，包括反壟斷和監管部門的批准，目前預計將於2024年中期完成。
It is anticipated that all sale proceeds will be used to repay certain amounts outstanding under the loan agreement and that there will be no distribution to the company or its shareholders.
預計所有出售收益將用於償還貸款協議下的某些未償還款項，並且不會向公司或其股東進行分配。
The appointment of the Administrators and sale to Roche represents the culmination of LumiraDx's previously announced strategic review process.
管理人員的任命和出售給羅氏代表了LumiraDX先前宣佈的戰略審查程序的高潮。
Price Action: LMDX shares are down 22.30% at $0.49 during the premarket session on the last check Tuesday.
價格走勢：週二最後一次盤前交易中，LMDX股價下跌22.30％，至0.49美元。